Study of Therapeutic Bacteria for Atopic Dermatitis

People with eczema (atopic dermatitis) may be particularly susceptible to bacterial, viral, and fungal skin infections. Treatment cannot cure atopic dermatitis, but it can control it. This study tests a new approach to therapy using live bacteria (also called a probiotic). NIAID researchers will introduce the bacteria Roseomonas mucosa from healthy skin onto the skin of someone with atopic dermatitis to see if it helps to treat the disease.

What does the study involve?

Some blood tests are required for enrollment. The study evaluates the safety and effectiveness of R mucosa in patients ages 3-17 years. All participants will self-administer R mucosa twice a month for four months and assessments will occur on a monthly basis. Participants will then be monitored for up to one year to evaluate long-term effectiveness and safety.

Who can participate?

You may be eligible to participate in this study if:

  • You are at least 3 years of age
  • Your doctor has made the diagnosis of atopic dermatitis
  • Your rash is located on your forearms or elbow area
  • You are willing to make at least 6 visits to NIH during the year-long study

Where is the study taking place?

The study is being conducted at the NIH Clinical Center in Bethesda, Maryland, which is accessible by car and public transportation.

How much does it cost?

There is no charge to participate in this research study. All study-related medical care, including clinic visits and procedures, are provided free of charge.

Will I receive payment?

Modest financial compensation will be provided to study participants. Travel expenses may be reimbursed.

To learn more about the study of Cutaneous Treatment Efficacy of Roseomonas in Atopic Dermatitis (trial ID: NCT03018275), visit clinicaltrials.gov.

Content last reviewed on March 15, 2018